Entremed Scientists Report Potent Antiangiogenic Effects in Preclinical Studies of Recombinant Human Endostatin ™ and Angiostatin® Protein at the American Association for Cancer Research Annual Meeting

Recombinant Human Endostatin ™ Manufacturing Process Validated for the Production of Material for Human Trials

ROCKVILLE, Md April 13, 1999/Wired Bird at PSA Rising/ - EntreMed, Inc. (NASDAQ:ENMD) scientists presented several preclinical studies demonstrating the efficacy of Endostatin™ protein and Angiostatin® protein in inhibiting tumor growth this week at the 90th Annual Meeting of the American Association for Cancer Research (AACR) in Philadelphia, Pennsylvania. EntreMed also reported its manufacturing process for the production of recombinant human (rhu) Endostatin™ protein yields soluble, well characterized product in quantities sufficient for early clinical trials. In all, thirteen abstracts were presented on Endostatin™ protein and Angiostatin® protein by EntreMed scientists and other researchers from around the world. Endostatin™ protein and Angiostatin® protein are potent, naturally-occurring, angiogenesis inhibitors that specifically inhibit endothelial cell proliferation, angiogenesis and tumor growth.

In a second EntreMed abstract presented at the AACR mini-symposium on angiogenesis, entitled "Recombinant Human Angiostatin®: Dose-Dependent Inhibition of Early and Late Stage Established Metastases in Mice," EntreMed scientists presented data showing that their recombinant Angiostatin® protein markedly inhibited malignant melanoma in both early stage and late stage metastatic cancer in the lungs of mice. EntreMed researchers cloned the human Angiostatin® protein and now produce it in scale-up fermentation using the yeast Pichia pastoris.

In total, EntreMed researchers gave nine presentations of the Company's own research on its antiangiogenic product candidates and their respective effects in preclinical cancer models at the AACR Annual Meeting, including two from the Company's internal discovery program - "Enantiomeric, Dependent Antimetastatic Activity of a Stable Thalidomide Analog," and "Tissue Factor Pathway Inhibitor (TFPI) Is an Inhibitor of Angiogenesis." A complete list of EntreMed's scientific study abstracts is attached.

Dr. Joanna C. Horobin, EntreMed's Senior Vice President of Commercial Development, commented on the presentations: "EntreMed is pleased to provide progress reports on our antiangiogenic product portfolio at this prestigious scientific meeting. We remain on schedule to commence Phase I safety trials of Endostatin™ protein later this year."

The AACR is a professional society with more than 14,000 laboratory and clinical scientists engaged in cancer research in the United States, Canada and 60 other countries. Its principal activities include fostering advances in cancer and biomedical research through programs that promote scientific education and communication, meetings to present significant new discoveries in cancer and the publishing of four major peer-reviewed journals including Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation and Cancer Epidemiology, Biomarkers & Prevention.

Rockville, Md.-based EntreMed, Inc., The Angiogenesis CompanyTM, is a leader in the field of antiangiogenesis research, which studies the inhibition of abnormal blood vessel growth recently associated with a broad range of diseases. The Company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. For further information, please visit the EntreMed web site at www.entremed.com.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

SOURCE Entremed, Inc.

Cover WiredBird Content Policy

To contact us or report problems with pages E-mail PSA Rising ©1999 prostate cancer survivor news http://www.psa-rising.com to top

Page last modified 08 September 1999